BioMarin to seek revised Kuvan label on data that will inform PEG-PAL Phase III
This article was originally published in Scrip
Executive Summary
BioMarin Pharmaceutical has new neurocognitive data for Kuvan (sapropterin dihydrochloride) in the treatment of phenylketonuria (PKU) that - assuming a label change is approved - could boost the approved drug's uptake in the market and aid in development of the company's investigational PKU therapy PEG-PAL.